UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006504 |
|---|---|
| Receipt number | R000007716 |
| Scientific Title | Assessment of beneficial effects on left ventricular hypertrophy and diastolic function by metformin in hypertensive patients with type2 DM |
| Date of disclosure of the study information | 2011/10/07 |
| Last modified on | 2018/04/12 23:18:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Assessment of beneficial effects on left ventricular hypertrophy and diastolic function by metformin in hypertensive patients with type2 DM
Acronym
Assessment of beneficial effects on left ventricular hypertrophy and diastolic function by metformin
Scientific Title
Assessment of beneficial effects on left ventricular hypertrophy and diastolic function by metformin in hypertensive patients with type2 DM
Scientific Title:Acronym
Assessment of beneficial effects on left ventricular hypertrophy and diastolic function by metformin
Region
| Japan |
Condition
Condition
Hypertension,
Type 2 diabetes mellitus
Classification by specialty
| Medicine in general | Cardiology | Endocrinology and Metabolism |
| Geriatrics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To assess beneficial effects on left ventricular hypertrophy and diastolic function by metformin in hypertensive patients with type 2 diabetes mellitus using left ventricular mass index of echocardiography and blood biomarkers of heart failure
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Explanatory
Developmental phase
Phase IV
Assessment
Primary outcomes
1) Left ventricular mass and diastolic function by echocardiography (LVMI, E/A, DT, E/e')
2) Blood biomarker of heart failure (BNP, NT-proBNP)
Key secondary outcomes
1) Left ventricular mass by cardiac MRI
2) Electrocardiogram (assessment of autonomic function by R-R variation)
3) Exploratory analysis
To search a patient group in which metformin is useful by carrying out a stratified analysis of patient background male/female, extent and duration of diabetes mellitus, BMI, etc)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Oral diabetic agents except metformin, and pioglitazone
Interventions/Control_2
Metgluco (drug code) 500-1, 500mg/day p.o.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 75 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) 30=<age<75 years old (male and female)
2) Patients with hypertension (blood pressure is less than 140/90mmHg and stable for at least 1 month. The subjects include patients who receive antihypertensive medication. LVEF>=50%)
3) Type 2 diabetes mellitus patients with HbA1c>=6.5%. These exclude patients who receive medication with metformin and pioglitazone for 3 months before enrollment. These also exclude patients who receive insulin therapy for 1 year before enrollment.
4) Patients without renal dysfunction (Serum creatinine: <1.3mg/dL (male), <1.2 mg/dL (female))
5) Patients with informed consent of taking part in clinical research
Key exclusion criteria
1) Patients with type 1 and 2 diabetes mellitus under insulin treatment or secondary diabetes patients
2) Patients with serious hepatic dysfunction/hepatic cirrhosis
3) Patients with unstable angina, acute myocardial infarction, severe coronary artery disease patients (Left Main Trunk or triple-vessel disease)
4) Patients with chronic atrial fibrillation or pacemaker patients
5) Patients with past lactic acidosis
6) Patients with severe dysfunction in cardiovascular system, pulmonary function disabled shock (such as heart failure, myocardial infarction, pulmonary embolism) and with easy to develop other hypoxemia
7) Heavy drinker
8) Patients with gastrointestinal disorder such as diarrhea and vomiting that worried dehydration
9) Patients with severe ketosis, diabetic coma orprecoma patients
10) Patients with severe infection, perioperative, severe injury
11) Those with malnutrition, starvation, debilitation, pituitary insufficiency or adrenal insufficiency patients
12) Those with allergic response for the object medicine
13) Pregnant and lactating patients or the patient who wishes to become pregnant
14) Those who judged inappropriate for the clinical trial
Target sample size
440
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Koh Ono |
Organization
National Hospital Organization Kyoto Medical Center
Division name
Division of Translational Research
Zip code
Address
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan
TEL
075-641-9161
kohono@kuhp.kyoto-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Koji Hasegawa |
Organization
National Hospital Organization Kyoto Medical Center
Division name
Division of Translational Research
Zip code
Address
1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan
TEL
075-641-9161
Homepage URL
koj@kuhp.kyoto-u.ac.jp
Sponsor or person
Institute
National Hospital Organization Kyoto Medical Center
Institute
Department
Personal name
Funding Source
Organization
National Hospital Organization Kyoto Medical Center
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
National Hospital Organization Kyoto Medical Center
Other related organizations
Co-sponsor
Graduate School of Medicine, Kyoto University
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
北海道がんセンター（北海道）、北海道医療センター（北海道）、函館病院（北海道）、八戸病院（青森県）、岩手病院（岩手県）、栃木病院（栃木県）、宇都宮病院（栃木県）、高崎総合医療センター（群馬県）、西群馬病院（群馬県）、埼玉病院（埼玉県）、東京医療センター（東京都）、横浜医療センター（神奈川県）、金沢医療センター（石川県）、鈴鹿病院（三重県）、滋賀病院（滋賀県）、京都医療センター（京都府）、大阪医療センター（大阪府）、神戸医療センター（兵庫県）、姫路医療センター（兵庫県）、兵庫中央病院（兵庫県）、南和歌山医療センター（和歌山県）、浜田医療センター（島根県）、岡山医療センター（岡山県）、呉医療センター（広島県）、東広島医療センター（広島県）、東徳島医療センター（徳島県）、高松医療センター（香川県）、愛媛病院（愛媛県）、九州医療センター（福岡県）、大牟田病院（福岡県）、嬉野医療センター（佐賀県）、長崎川棚医療センター（長崎県）、熊本医療センター（熊本県）、大分医療センター（大分県）、宮崎東病院（宮崎県）、鹿児島医療センター（鹿児島県）
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 10 | Month | 07 | Day |
Related information
URL releasing protocol
https://www.nhocrc.jp/ABLEMETpage.html
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 09 | Month | 16 | Day |
Date of IRB
Anticipated trial start date
| 2011 | Year | 10 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 09 | Month | 01 | Day |
Date of closure to data entry
| 2016 | Year | 09 | Month | 01 | Day |
Date trial data considered complete
| 2016 | Year | 09 | Month | 01 | Day |
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 10 | Month | 07 | Day |
Last modified on
| 2018 | Year | 04 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007716
